Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.59 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435921 | 1.00 | ACE (0.59) | ACEFKBP1AACE2TSHRALDH1A1 | |
| SCHEMBL6439093 | 0.93 | ACE (0.62) | ACEFKBP1AACE2 | |
| SCHEMBL7426069 | 0.92 | ACE (0.59) | ACEFKBP1AACE2 | |
| SCHEMBL6436340 | 0.92 | ACE (0.59) | ACEFKBP1AACE2 | |
| SCHEMBL8366880 | 0.91 | ACE (0.56) | ACEFKBP1A | |
| SCHEMBL7428633 | 0.90 | ACE (0.57) | ACEFKBP1AACE2TSHRALDH1A1 | |
| SCHEMBL6437871 | 0.90 | ACE (0.57) | ACEFKBP1AACE2TSHRALDH1A1 | |
| SCHEMBL6435613 | 0.90 | ACE (0.56) | ACEFKBP1AACE2TSHRALDH1A1 | |
| SCHEMBL7423817 | 0.90 | ACE (0.56) | ACEFKBP1AACE2TSHRALDH1A1 | |
| SCHEMBL25448062 | 0.89 | ACE (0.57) | ACEFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |